Clinical trial
Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III…
NCT00153803 · Dartmouth-Hitchcock Medical Center, Other · Completed
Key facts
| NCT number | NCT00153803 |
|---|---|
| Title | Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) |
| Official title | A National Web-Based Randomized Phase III Study of Erlotinib or Placebo Following Concurrent Docetaxel, Carboplatin, and Thoracic Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (D0410). |
| Lead sponsor | Dartmouth-Hitchcock Medical Center, Other |
| Collaborators | Sanofi Industry Genentech, Inc. |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung, Non-small Cell Lung Cancer, NSCLC |
| Intervention type | Drug |
| Interventions | Erlotinib (tarceva), Placebo |
| Enrollment | 245 |
| Start date | May 1, 2005 |
| Primary completion | Apr 1, 2014 |
| Completion | Apr 1, 2014 |
| First posted | Sep 12, 2005 |
| Last update posted | Sep 6, 2019 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: